Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibrinolysis for Indwelling Pleural Catheter in MPE
NCT03678090Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Dec 2018
- Primary completion
- Feb 2020
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 2, randomised trial of tissue-plasminogen activator in malignant pleural effusion (MPE) (2 arms), sponsored by Yale University. Primary endpoints: Improvement in patient chest X-ray at 40 days and Improvement on the modified Borg dyspnea scale after tPA at 40 days. Planned start Dec 2018; status: withdrawn.
02
Drugs
tissue-plasminogen activator
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT03678090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678090.